CLINICAL SIGNIFICANCE OF THE RESULTS OF THE DAPA HF (Dapaglifl ozin and Prevention of Adverse-Outcomes in Heart Failure) TRIAL FOR PATIENTS AND PHYSICIANS. CONSENSUS OF THE EXPERT COUNCIL

Gulmira Ch  ALIPOVA; Anna V  BAZAROVA; Nazira K  BAZAROVA; Rimma B  BAZARBEKOVA; Gulnara G  BEDELBAEVA; Irina V  GUSEVA; Gulnara A  JUNUSBEKOVA; Ainur K  DOSSANOVA; Gulnar K  JUSSUPOVA; Murat A  MUKAROV; Akmaral A  NURBEKOVA; Tatiana M  OYLAROVA; Zhannat S  TAUBALDIEVA; Sergey N  TERESHCHENKO; Meyramgul K  TUNDYBAEVA

doi:10.31082/1728-452X-2021-223-1-2-14

Authors

Gulmira Ch ALIPOVA Turkestan Regional Cardiology Center
Anna V BAZAROVA Astana Medical University JSC
Nazira K BAZAROVA Polyclinic No 3
Rimma B BAZARBEKOVA Kazakh Medical University of Continuing Education
Gulnara G BEDELBAEVA Asfendiyarov Kazakh National Medical University
Irina V GUSEVA Polyclinic No 2
Gulnara A JUNUSBEKOVA Asfendiyarov Kazakh National Medical University
Ainur K DOSSANOVA Kazakh Medical University of Continuing Education
Gulnar K JUSSUPOVA Astana Medical University
Murat A MUKAROV National Scientific Cardiac Surgery Center
Akmaral A NURBEKOVA Asfendiyarov Kazakh National Medical University
Tatiana M OYLAROVA Polyclinic No 10
Zhannat S TAUBALDIEVA National Scientific Medical Center
Sergey N TERESHCHENKO National Medical Research Center for Cardiology
Meyramgul K TUNDYBAEVA Asfendiyarov Kazakh National Medical University

DOI:

https://doi.org/10.31082/1728-452X-2021-223-1-2-14

Keywords:

chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus

Abstract

The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease.

CLINICAL SIGNIFICANCE OF THE RESULTS OF THE DAPA HF (Dapaglifl ozin and Prevention of Adverse-Outcomes in Heart Failure) TRIAL FOR PATIENTS AND PHYSICIANS. CONSENSUS OF THE EXPERT COUNCIL

Authors

DOI:

Keywords:

Abstract

Downloads

Published

Issue

Section

Most read articles by the same author(s)

issn